Submitted Successfully!
To reward your contribution, here is a gift for you: A free trial for our video production service.
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Version Summary Created by Modification Content Size Created at Operation
1
Masaru Tanaka
 -- 2894 2023-11-20 10:10:58 |
2 format correct
Mona Zou
Meta information modification 2894 2023-11-21 03:10:12 |

Video Upload Options

Do you have a full video?
Send video materials Upload full video

Confirm

Are you sure to Delete?
Yes No
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
Tanaka, M.; Szabó, �.; Körtési, T.; Szok, D.; Tajti, J.; Vécsei, L. From CGRP to PACAP: Novel Antimigraine Drug Targets. Encyclopedia. Available online: https://encyclopedia.pub/entry/51797 (accessed on 04 May 2024).
Tanaka M, Szabó �, Körtési T, Szok D, Tajti J, Vécsei L. From CGRP to PACAP: Novel Antimigraine Drug Targets. Encyclopedia. Available at: https://encyclopedia.pub/entry/51797. Accessed May 04, 2024.
Tanaka, Masaru, Ágnes Szabó, Tamás Körtési, Délia Szok, János Tajti, László Vécsei. "From CGRP to PACAP: Novel Antimigraine Drug Targets" Encyclopedia, https://encyclopedia.pub/entry/51797 (accessed May 04, 2024).
Tanaka, M., Szabó, �., Körtési, T., Szok, D., Tajti, J., & Vécsei, L. (2023, November 20). From CGRP to PACAP: Novel Antimigraine Drug Targets. In Encyclopedia. https://encyclopedia.pub/entry/51797
Tanaka, Masaru, et al. "From CGRP to PACAP: Novel Antimigraine Drug Targets." Encyclopedia. Web. 20 November, 2023.
From CGRP to PACAP: Novel Antimigraine Drug Targets
Edit
This entry is adapted from the peer-reviewed paper 10.3390/cells12222649

Migraine is a neurovascular disorder that can be debilitating for individuals and society. Current research focuses on finding effective analgesics and management strategies for migraines by targeting specific receptors and neuropeptides. Nonetheless, newly approved calcitonin gene-related peptide (CGRP) monoclonal antibodies (mAbs) have a 50% responder rate ranging from 27 to 71.0%, whereas CGRP receptor inhibitors have a 50% responder rate ranging from 56 to 71%. To address the need for novel therapeutic targets, researchers are exploring the potential of another secretin family peptide, pituitary adenylate cyclase-activating polypeptide (PACAP), as a ground-breaking treatment avenue for migraine. Preclinical models have revealed how PACAP affects the trigeminal system, which is implicated in headache disorders. Clinical studies have demonstrated the significance of PACAP in migraine pathophysiology; however, a few clinical trials remain inconclusive: the pituitary adenylate cyclase-activating peptide 1 receptor mAb, AMG 301 showed no benefit for migraine prevention, while the PACAP ligand mAb, Lu AG09222 significantly reduced the number of monthly migraine days over placebo in a phase 2 clinical trial. Meanwhile, another secretin family peptide vasoactive intestinal peptide (VIP) is gaining interest as a potential new target.

migraine disorders headache disorders nociceptive pain analgesics calcitonin gene-related peptide pituitary adenylate cyclase-activating polypeptide (PACAP) vasoactive intestinal peptide adrenomedullin neuropeptides drug development

1. Pituitary Adenylate Cyclase-Activating Peptide and Vasoactive Intestinal Peptide

PACAP is a multi-functional peptide that has therapeutic potential in a variety of pathophysiological conditions and represents a promising avenue for intervention. PACAP is a neuropeptide that plays a crucial role in both neural and endocrine functions [1]. This peptide is widely distributed throughout the body and is involved in diverse physiological processes, including circadian rhythm and immune system regulations, modulation of pain perception, and stress response [2]. PACAP also has neuroprotective effects and has been shown to support nerve cell survival and regeneration in various neurological disorders [3]. GPCRs control the signaling pathways and cause the activation of adenylate cyclase (AC), the release of cyclic AMP, and the activation of protein kinase A (PKA) and calcium channels [4][5]. PACAP is a multi-functional peptide that has therapeutic potential in a variety of pathophysiological conditions and represents a promising avenue for therapeutic intervention [6].

2. Background

PACAP was found in ovine hypothalamic extracts in 1989. It is a 38-amino acid peptide hormone that stimulates AC activity in the pituitary gland [7]. Subsequently, it was found to be widely distributed in the central and peripheral nervous systems, as well as in non-neural tissues, including the adrenal gland, pancreas, gut, and reproductive system [8]. PACAP exists in three biologically active forms: PACAP1–38, 6–38-amino acid form of PACAP (PACAP6–38), and PACAP1–27 [9]. PACAP-related peptide (PRP) is also a member of the PACAP family [10]. Radioimmunoassay demonstrated that PACAP1–38 levels were approximately 60 times greater than PACAP1–27 levels and 10 times greater than PRP levels [11].
Since its discovery, PACAP has been extensively studied for its potent neuroprotective effects against a diverse range of neurological disorders, including stroke, traumatic brain injury, Parkinson’s disease, and Alzheimer’s disease [12][13]. Recent findings suggest that PACAP may also play a key role in the regulation of immune cell function and cytokine production, highlighting its potential as a therapeutic target for immune-mediated diseases such as rheumatoid arthritis, multiple sclerosis, and asthma [14]. Furthermore, PACAP has been implicated in the regulation of energy metabolism, making it a promising therapeutic agent for the treatment of metabolic disorders such as obesity and diabetes [15]. Overall, the growing body of evidence on the multifunctional properties of PACAP highlights its potential as a novel therapeutic target for a wide range of diseases.
VIP is a 28-amino acid polypeptide that was first characterized in 1970. It is secreted by cells throughout the intestinal tract and is widespread in many internal organs and systems [16]. VIP plays important roles in many biological functions, such as stimulation of contractility in the heart, vasodilation, promoting neuroendocrine–immune communication, lowering arterial blood pressure, and anti-inflammatory and immune-modulatory activity [17]. VIP stimulates the secretion of electrolytes and water by the intestinal mucosa and acts as a neurotransmitter, inducing a relaxation effect in some tissues [18]. VIP is also involved in the pathophysiology of various diseases, including osteoarthritis, cancer, and autoimmune disorders [17]. Furthermore, VIP is implicated in the physiological and pathophysiological roles of migraine [19].

3. Receptor and Signaling Mechanisms of PACAP and VIP

PACAP plays an important role in a wide range of biological processes such as feeding behavior, stress response, neuroprotection, and regulation of neurotransmitter release. It activates three different GPCRs named PAC1, vasoactive intestinal peptide receptor (VPAC) 1, and VPAC2; these receptors are widely expressed in the central and peripheral nervous systems, endocrine systems, and immune systems [20]. The binding of PACAP to these receptors leads to the activation of multiple signaling mechanisms [21].
Activation of the PAC1 receptor by PACAP leads to the activation of the adenylyl cyclase enzyme, which in turn leads to the production of cyclic adenosine monophosphate (cAMP) and the activation of PKA [22]. It also triggers the activation of phospholipase C, which leads to the breakdown of phosphatidyl inositol 4,5-bisphosphate (PIP2) into inositol triphosphate and diacylglycerol (DAG), which activates protein kinase C (PKC) [23]. On the other hand, VPAC1 and VPAC2 receptor activation leads to AC enzyme activation, which leads to the generation of cAMP and the activation of PKA [24]. Also, PACAP signaling turns on calcium signaling, which causes intracellular calcium to be released and calcium/calmodulin-dependent kinase II to be activated [25]. PACAP signaling also activates the mitogen-activated protein kinase (MAPK), extracellular signal-regulated kinase (ERK), and jun N-terminal kinase signaling pathways [26]. These signaling mechanisms contribute to the diverse biological effects of PACAP on cellular functions. The regulation of PACAP gene expression is presented in Figure 1.
Cells 12 02649 g002
Figure 1. PACAP receptors signaling to ERK activation. AC, adenylate cylase; ATP: adenosine monophosphate; cAMP: cyclic adenosine monophosphate; DAG: diacylglycerol; ERK, extracellular signal-regulated kinase; Gs and Gq: stimulatory G protein; MEK: mitogen-activated protein kinase kinase; PKA: protein kinase A; PKC: protein kinase C; PACAP: pituitary adenylate cyclase-activating polypeptide; PAC1: PACAP 1 receptor; PIP2: phosphatidylinositol bisphosphate; VPAC1: vasoactive intestinal peptide receptor type 1; VPAC2: vasoactive intestinal peptide receptor type 2.
PACAP and VIP are neuropeptides that interact specifically with three receptors (VPAC1, VPAC2, and PAC1) from the class II B GPCR family [27]. The similarities between PACAP and VIP in receptor and signaling mechanisms include the following: PACAP and VIP share nearly 70% amino acid sequence identity; PACAP binds with high affinity to all three receptors, while VIP binds with high affinity to VPAC1 and VPAC2 receptors and has a thousand fold lower affinity for the PAC1 receptor compared to PACAP; both PACAP and VIP receptors are preferentially coupled to Gαs, leading to activation of AC, subsequent cAMP production, and activation of PKA; and PKA may in turn activate ERKs, PACAP and VIP receptor-mediated signaling pathways [28][29][30][31]. Due to the wide distribution of VIP and PACAP receptors in the body, potential therapeutic applications of drugs targeting these receptors, as well as expected unwanted side effects, are numerous [32]. Designing selective therapeutics targeting these receptors remains challenging due to their structural similarities.

4. Role of PACAP and VIP in Migraine

PACAP has been strongly associated with the pathophysiology of migraine. PACAP is found in high levels in the trigeminal nerve, which is known to play a critical role in this condition. PACAP is known to increase the sensitivity of the trigeminal nerve, cause dilation of blood vessels in the brain, and trigger inflammation. All these biological effects have been implicated in the development of migraine attacks [33]. Several studies have been conducted to investigate the role of PACAP in migraine. One study showed that PACAP levels in the blood are significantly higher in migraine patients during an attack compared to headache-free controls [34]. This study suggests that PACAP could be used as a potential biomarker for migraine. Another study demonstrated that the venous infusion of PACAP into migraine patients resulted in the development of migraine-like attacks [35]. This finding strongly supports the hypothesis that PACAP plays a crucial role in the pathophysiology of migraine and suggests that blocking PACAP could be a potential therapeutic target for the treatment of migraines. The role of PACAP in migraine pathology is well established, and there is strong evidence that this neuropeptide plays a crucial role in the development of migraine attacks. Further research is needed to better understand the mechanism of action of PACAP and to develop new pharmacological agents that target PACAP for the treatment of migraines.
Both CGRP and PACAP are multifunctional peptides with many roles in the nervous, cardiovascular, respiratory, gastrointestinal, and reproductive systems. They play a role in vasodilation, neurogenic inflammation, and nociception. While CGRP plays an integral role in migraine, PACAP is likely to play a similar but distinct role as CGRP based on similarities and differences observed in both clinical and preclinical studies [36]. In rodent models, the PACAP pathway appears to be independent of the CGRP pathway, suggesting that CGRP and PACAP act in parallel ways that cause a migraine-like symptom [37]. In migraine without aura, the first double-blinded placebo-controlled study reported that 33% of the patients developed delayed migraine attacks after CGRP administration [38]. The studies have identified the involvement of two endogenous neuropeptides, CGRP and PACAP, in the pathogenesis of migraines [39].
VIP has also been implicated in the pathophysiology of migraine [40]. The similarities between PACAP and VIP in their roles in pathogenesis include the following: PACAP and VIP are released in conjunction with migraine and cluster headache attacks [41]; PACAP and VIP are potent vasodilators and can cause migraine-like attacks when infused into people [42]; a 2-h infusion of VIP caused migraine attacks, indicating that VIP plays a significant role in pathophysiology and intravenous administration of PACAP-38 caused headaches in all healthy subjects and migraine-like attacks in 58% of patients with a history of migraine without aura [43][44]; PACAP and VIP receptors are preferentially coupled to Gαs, leading to activation of AC, subsequent cAMP production, and activation of PKA [45]; PKA may in turn activate ERKs [46]; PACAP and VIP receptor-mediated signaling pathways are shown to share activities, including vasodilation, neurogenic inflammation, and nociception in rodents [47]; PACAP and VIP receptors provide a rich set of targets to complement and augment the current CGRP-based migraine therapeutics; VPAC1 receptors play a dominant role in PACAP-induced vasorelaxation in female mice [48]. Also, PG 99-465, a selective VPAC2 receptor antagonist that has been used in a number of physiological studies, has been shown to have significant activity at VPAC1 and PAC1 receptors [49].

5. Preclinical Studies

In addition to in vitro systems, a variety of organisms are used in experimental medicine [50][51][52]. Understanding the effects of endogenous neuropeptides, neurohormones, and metabolites has advanced significantly thanks to the information gathered using laboratory animals [53][54][55][56][57][58]. Animal models are a crucial tool for bridging the knowledge gap between data- and hypothesis-driven benchwork and its application to clinical bedside management. PACAP has been extensively studied as a neuromodulator in the trigeminal nociceptive pathway [59]. Preclinical studies have shown that PACAP is involved in the transmission of pain signals from the periphery to the central nervous system and is therefore a potential target for the treatment of migraine and other headache disorders [60][61].
In animal models, PACAP has been shown to play a role in trigeminal sensitization, which is the process by which nociceptive signals become amplified and persistent, leading to chronic pain [62]. Studies have also found that PACAP is involved in the activation of inflammatory pathways in the trigeminal nerve, further contributing to pain and inflammation [63]. In addition, PACAP has been implicated in the regulation of blood flow to the brain, which may also play a role in headache pathophysiology [64] and other neurological [65] or neuropsychological conditions [11]. In an experimental model of migraine, intraperitoneal administration of nitroglycerol caused marked photophobia and meningeal vasodilatation, and increased the number of c-fos-positive activated neurons in the TNC in wild-type mice but not in PACAP1–38-deficient mice [66]. In line with this, an increased concentration of PACAP1–38 was detected in the TNC after the activation of the TS in different animal models [67][68].
PAC1 receptor antagonists include PACAP6–38, N-stearyl-[Nle17] neurotensin-(6-11)/VIP-(7-28), deletion mutants of maxadilan, M65, and Max.d.4, and synthesized small-molecule acyl hydrazides, including PG 97-269 [69]. PACAP6–38 has been used as a PAC1 receptor antagonist in many studies, but it has an affinity for VPAC2 receptors [70]. N-stearyl-[Nle17] neurotensin-(6-11)/VIP-(7-28) (SNV) is a chimeric peptide analog that antagonizes the VIP2/PACAP receptor subclass. SNV is a better mitogen for the keratinocytic cell line and can increase AC activity in rat brain membranes 100 times more than VIP1-28 [71][72]. No migraine-related studies have been documented. The maxadilan is a vasodilator peptide derived from the salivary glands of sandflies. Its deletion mutants, M65 and Max.d.4, have been reported to be selective PAC1 receptor antagonists but have not been extensively used due to problems of availability [73][74]. PG 97-269 is a selective VPAC1 receptor antagonist with negligible affinity for the PACAP1 receptor. It did not stimulate AC activity but inhibited competitively the effect of VIP on AC activity in cells expressing the VIP1 receptor [72]. VIP and PACAP-induced vasodilation were partially blocked by PG 97-269, indicating that PACAP and VIP may play a role in migraine pathophysiology and that PG 97-269 may have therapeutic potential for migraine [75]. Thus, preclinical studies suggest that concentrating on the PACAP signaling pathways in the trigeminal nociceptive system could be an effective strategy for discovering novel treatments for headache disorders. However, more research is needed to fully understand the mechanisms underlying PACAPs’ role in headache pathophysiology and to develop effective and safe PACAP-targeted therapies.
VIP plays a key role in sensory processing and the modulation of pain pathways in the trigeminal system. In preclinical studies, VIP has been shown to change the activity of nociceptive neurons in the trigeminal ganglion and make the TNC more sensitive, which can cause chronic pain or migraines [76]. In response to noxious stimuli, the trigeminal sensory neurons release VIP. This can activate VIP receptors on nearby neurons and cause the release of a number of signaling molecules involved in pain amplification [77]. VIP-mediated sensitization of trigeminal neurons can lead to hyperexcitability and increased responsiveness to noxious stimuli, which may contribute to the development and maintenance of chronic pain or migraine [78]. Targeting VIP signaling pathways may therefore represent a promising approach for the development of novel therapies for chronic pain or migraine.

6. Clinical Studies

A growing body of clinical research suggests that PACAP plays an important role in migraine pathophysiology. Patients with migraines exhibit higher levels of PACAP compared to control groups [79]. PACAP is a neuropeptide recognized for its involvement in the activation of nociceptive pathways, contributing to the development of migraines. The high levels of PACAP in migraineurs have been associated with increased headache severity and frequency, and this has led to the exploration of PACAP as a therapeutic target for treatment [80]. In migraineurs without aura, the development of PACAP1–38-evoked migraine-like attacks was independent of the severity of family load [44][81]. In the same study, 90 min after the injection, the levels of numerous migraine-related molecular markers were increased in the plasma of patients [82]. Magnetic resonance imaging angiography examinations revealed that PACAP1–38-induced headache was associated with prolonged vasodilatation of the middle meningeal artery (MMA) but not the middle cerebral artery (MCA). Sumatriptan, an antimigraine medication, was able to alleviate the headache, which mirrored the contraction of the MMA but not the MCA, indicating that PACAP1–38-induced headaches may originate from extracerebral arteries [83].
An increasing number of clinical studies have shown that targeting PACAP signaling may be a promising therapeutic strategy for migraine treatment. In terms of safety, PACAP has been generally well tolerated in clinical trials [84]. One study found that PACAP induces headaches via sustained vasodilation and that targeting the PACAP pathway may be a promising approach for treatment [85]. AMG 301, a mAb that targets the PAC1 receptor, was administered to patients with episodic or chronic migraines in a randomized, double-blind, placebo-controlled phase 2 study. There was no significant difference between the AMG 301 group and the placebo group, suggesting that AMG 301 was ineffective for prevention [86][87]. On the other hand, the PACAP ligand mAb, Lu AG09222, was shown to reduce the number of monthly migraine days from baseline to weeks 1–4 of treatment statistically significantly more than placebo [88][89]. Additionally, the mAb targeting the PAC1 receptor, LY3451838, is currently undergoing phase 2 clinical trials for adults with treatment-resistant migraine. This trial is in progress, and the results are not yet available [90]. Overall, the efficacy and safety of PACAP as a migraine treatment in clinical studies suggest that it is a promising option for patients with this debilitating condition. Further research is needed to fully understand the potential of PACAP as a treatment for migraines, but the current evidence is encouraging.
VIP infusion has been studied in the context of migraines, with a particular focus on its potential to provoke migraine attacks and its role in pathophysiology. A phase 2 clinical trial investigated the effects of a long-lasting infusion of VIP on headaches, cranial hemodynamics, and autonomic symptoms in episodic migraine patients without aura [91]. The study found that a 2-h infusion of VIP promoted long-lasting cranial vasodilation and delayed headaches in healthy volunteers, resembling the effect of prophylaxis. However, other studies have suggested that VIP infusions may actually provoke migraine attacks. For example, a randomized clinical trial found that a 2-h infusion of VIP caused migraine episodes, suggesting an important role of VIP in migraine pathophysiology [43]. It remains unclear whether the lack of migraine induction can be attributed to the only transient vasodilatory response after a 20-min infusion of VIP. Overall, the search results suggest that VIP infusion may have a role in migraine pathophysiology, but further research is needed to fully understand its effects and potential therapeutic applications.

References

  1. Rassler, B.; Blinowska, K.; Kaminski, M.; Pfurtscheller, G. Analysis of Respiratory Sinus Arrhythmia and Directed Information Flow between Brain and Body Indicate Different Management Strategies of fMRI-Related Anxiety. Biomedicines 2023, 11, 1028.
  2. Arimura, A. Perspectives on pituitary adenylate cyclase activating polypeptide (PACAP) in the neuroendocrine, endocrine, and nervous systems. Jpn. J. Physiol. 1998, 48, 301–331.
  3. Holland, P.R.; Barloese, M.; Fahrenkrug, J. PACAP in hypothalamic regulation of sleep and circadian rhythm: Importance for headache. J. Headache Pain 2018, 19, 20.
  4. Maugeri, G.; D’Amico, A.G.; Musumeci, G.; Reglodi, D.; D’Agata, V. Effects of PACAP on Schwann Cells: Focus on Nerve Injury. Int. J. Mol. Sci. 2020, 21, 8233.
  5. Johnson, G.C.; May, V.; Parsons, R.L.; Hammack, S.E. Parallel signaling pathways of pituitary adenylate cyclase activating polypeptide (PACAP) regulate several intrinsic ion channels. Ann. N. Y. Acad. Sci. 2019, 1455, 105–112.
  6. Clement, A.; Guo, S.; Jansen-Olesen, I.; Christensen, S.L. ATP-Sensitive Potassium Channels in Migraine: Translational Findings and Therapeutic Potential. Cells 2022, 11, 2406.
  7. Miyata, A.; Arimura, A.; Dahl, R.R.; Minamino, N.; Uehara, A.; Jiang, L.; Culler, M.D.; Coy, D.H. Isolation of a novel 38 residue-hypothalamic polypeptide which stimulates adenylate cyclase in pituitary cells. Biochem. Biophys. Res. Commun. 1989, 164, 567–574.
  8. Denes, V.; Geck, P.; Mester, A.; Gabriel, R. Pituitary Adenylate Cyclase-Activating Polypeptide: 30 Years in Research Spotlight and 600 Million Years in Service. J. Clin. Med. 2019, 8, 1488.
  9. Vaudry, D.; Nakamachi, T.; Basille, M.; Wurtz, O.; Fournier, A.; Shoida, S. Hypophysis Adenylate Cyclase Activating Polypeptide. In Handbook of Biologically Active Peptides, 2nd ed.; Academic Press: Boston, MA, USA, 2013; Available online: https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/hypophysis-adenylate-cyclase-activating-polypeptide (accessed on 28 August 2023).
  10. Tam, J.K.; Lee, L.T.; Chow, B.K. PACAP-related peptide (PRP)—Molecular evolution and potential functions. Peptides 2007, 28, 1920–1929.
  11. Köves, K.; Szabó, E.; Kántor, O.; Heinzlmann, A.; Szabó, F.; Csáki, Á. Current State of Understanding of the Role of PACAP in the Hypothalamo-Hypophyseal Gonadotropin Functions of Mammals. Front. Endocrinol. 2020, 11, 88.
  12. Lee, E.H.; Seo, S.R. Neuroprotective roles of pituitary adenylate cyclase-activating polypeptide in neurodegenerative diseases. BMB Rep. 2014, 47, 369–375.
  13. Sadanandan, N.; Cozene, B.; Park, Y.J.; Farooq, J.; Kingsbury, C.; Wang, Z.J.; Moscatello, A.; Saft, M.; Cho, J.; Gonzales-Portillo, B.; et al. Pituitary Adenylate Cyclase-Activating Polypeptide: A Potent Therapeutic Agent in Oxidative Stress. Antioxidants 2021, 10, 354.
  14. Waschek, J.A. VIP and PACAP: Neuropeptide modulators of CNS inflammation, injury, and repair. Br. J. Pharmacol. 2013, 169, 512–523.
  15. Xiao, X.; Qiu, P.; Gong, H.Z.; Chen, X.M.; Sun, Y.; Hong, A.; Ma, Y. PACAP ameliorates hepatic metabolism and inflammation through up-regulating FAIM in obesity. J. Cell Mol. Med. 2019, 23, 5970–5980.
  16. Gonkowski, S. Vasoactive Intestinal Polypeptide in the Carotid Body—A History of Forty Years of Research. A Mini Review. Int. J. Mol. Sci. 2020, 21, 4692.
  17. Jiang, W.; Wang, H.; Li, Y.S.; Luo, W. Role of vasoactive intestinal peptide in osteoarthritis. J. Biomed. Sci. 2016, 23, 63.
  18. Cao, S.G.; Wu, W.C.; Han, Z.; Wang, M.Y. Effects of psychological stress on small intestinal motility and expression of cholecystokinin and vasoactive intestinal polypeptide in plasma and small intestine in mice. World J. Gastroenterol. 2005, 11, 737–740.
  19. Jacobs, B.; Dussor, G. Neurovascular contributions to migraine: Moving beyond vasodilation. Neuroscience 2016, 338, 130–144.
  20. Langer, I.; Jeandriens, J.; Couvineau, A.; Sanmukh, S.; Latek, D. Signal Transduction by VIP and PACAP Receptors. Biomedicines 2022, 10, 406.
  21. Fizanne, L.; Sigaudo-Roussel, D.; Saumet, J.L.; Fromy, B. Evidence for the involvement of VPAC1 and VPAC2 receptors in pressure-induced vasodilatation in rodents. J. Physiol. 2004, 554 Pt 2, 519–528.
  22. Parsons, R.L.; May, V. PACAP-Induced PAC1 Receptor Internalization and Recruitment of Endosomal Signaling Regulate Cardiac Neuron Excitability. J. Mol. Neurosci. 2019, 68, 340–347.
  23. Bill, C.A.; Vines, C.M. Phospholipase C. Adv. Exp. Med. Biol. 2020, 1131, 215–242.
  24. Barloese, M.; Chitgar, M.; Hannibal, J.; Møller, S. Pituitary adenylate cyclase-activating peptide: Potential roles in the pathophysiology and complications of cirrhosis. Liver Int. 2020, 40, 2578–2589.
  25. Makhinson, M.; Chotiner, J.K.; Watson, J.B.; O’Dell, T.J. Adenylyl cyclase activation modulates activity-dependent changes in synaptic strength and Ca2+/calmodulin-dependent kinase II autophosphorylation. J. Neurosci. 1999, 19, 2500–2510.
  26. Johnson, G.L.; Lapadat, R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 2002, 298, 1911–1912.
  27. Lu, J.; Piper, S.J.; Zhao, P.; Miller, L.J.; Wootten, D.; Sexton, P.M. Targeting VIP and PACAP Receptor Signaling: New Insights into Designing Drugs for the PACAP Subfamily of Receptors. Int. J. Mol. Sci. 2022, 23, 8069.
  28. Hirabayashi, T.; Nakamachi, T.; Shioda, S. Discovery of PACAP and its receptors in the brain. J. Headache Pain 2018, 19, 28.
  29. Watanabe, J. Vasoactive Intestinal Polypeptide Receptor 1. In Methods in Enzymology; Academic Press: Boston, MA, USA, 2013; Available online: https://www.sciencedirect.com/topics/medicine-and-dentistry/vasoactive-intestinal-polypeptide-receptor-1 (accessed on 28 August 2023).
  30. Vasoactive Intestinal Polypeptide Receptor. Autonomic Neuroscience. 2007. Available online: https://www.sciencedirect.com/topics/neuroscience/vasoactive-intestinal-polypeptide-receptor (accessed on 28 August 2023).
  31. May, V.; Buttolph, T.R.; Girard, B.M.; Clason, T.A.; Parsons, R.L. PACAP-induced ERK activation in HEK cells expressing PAC1 receptors involves both receptor internalization and PKC signaling. Am. J. Physiol. Cell Physiol. 2014, 306, C1068–C1079.
  32. Hou, X.; Yang, D.; Yang, G.; Li, M.; Zhang, J.; Zhang, J.; Zhang, Y.; Liu, Y. Therapeutic potential of vasoactive intestinal peptide and its receptor VPAC2 in type 2 diabetes. Front. Endocrinol. 2022, 13, 984198.
  33. Sundrum, T.; Walker, C.S. Pituitary adenylate cyclase-activating polypeptide receptors in the trigeminovascular system: Implications for migraine. Br. J. Pharmacol. 2018, 175, 4109–4120.
  34. Liu, J.; Wang, G.; Dan, Y.; Liu, X. CGRP and PACAP-38 play an important role in diagnosing pediatric migraine. J. Headache Pain 2022, 23, 68.
  35. Schytz, H.W.; Olesen, J.; Ashina, M. The PACAP receptor: A novel target for migraine treatment. Neurotherapeutics 2010, 7, 191–196.
  36. Kuburas, A.; Russo, A.F. Shared and independent roles of CGRP and PACAP in migraine pathophysiology. J. Headache Pain 2023, 24, 34.
  37. Ernstsen, C.; Christensen, S.L.; Rasmussen, R.H.; Nielsen, B.S.; Jansen-Olesen, I.; Olesen, J.; Kristensen, D.M. The PACAP pathway is independent of CGRP in mouse models of migraine: Possible new drug target? Brain 2022, 145, 2450–2460.
  38. Christensen, C.E.; Ashina, M.; Amin, F.M. Calcitonin Gene-Related Peptide (CGRP) and Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP) in Migraine Pathogenesis. Pharmaceuticals 2022, 15, 1189.
  39. Anapindi, K.D.B.; Yang, N.; Romanova, E.V.; Rubakhin, S.S.; Tipton, A.; Dripps, I.; Sheets, Z.; Sweedler, J.V.; Pradhan, A.A. PACAP and Other Neuropeptide Targets Link Chronic Migraine and Opioid-induced Hyperalgesia in Mouse Models. Mol. Cell Proteomics 2019, 18, 2447–2458.
  40. Silvestro, M.; Iannone, L.F.; Orologio, I.; Tessitore, A.; Tedeschi, G.; Geppetti, P.; Russo, A. Migraine Treatment: Towards New Pharmacological Targets. Int. J. Mol. Sci. 2023, 24, 12268.
  41. Pellesi, L.; Chaudhry, B.A.; Vollesen, A.L.H.; Snoer, A.H.; Baumann, K.; Skov, P.S.; Jensen, R.H.; Ashina, M. PACAP38- and VIP-induced cluster headache attacks are not associated with changes of plasma CGRP or markers of mast cell activation. Cephalalgia 2022, 42, 687–695.
  42. Rasmussen, L.; Deligianni, C.; Christensen, C.E.; Karlsson, W.K.; Al-Khazali, H.M.; Van de Casteele, T.; Granhall, C.; Amin, F.M.; Ashina, M. The effect of Lu AG09222 on PACAP38- and VIP-induced vasodilation, heart rate increase, and headache in healthy subjects: An interventional, randomized, double-blind, parallel-group, placebo-controlled study. J. Headache Pain 2023, 24, 60.
  43. Pellesi, L.; Al-Karagholi, M.A.; De Icco, R.; Coskun, H.; Elbahi, F.A.; Lopez-Lopez, C.; Snellman, J.; Hannibal, J.; Amin, F.M.; Ashina, M. Effect of Vasoactive Intestinal Polypeptide on Development of Migraine Headaches: A Randomized Clinical Trial. JAMA Netw. Open 2021, 4, e2118543.
  44. Schytz, H.W.; Birk, S.; Wienecke, T.; Kruuse, C.; Olesen, J.; Ashina, M. PACAP38 induces migraine-like attacks in patients with migraine without aura. Brain 2009, 132 Pt 1, 16–25.
  45. Vu, J.P.; Germano, P.M.; Pisegna, J.R. Adenylate Cyclase. Adenylate Cyclases Are Enzymes That Catalyze the Conversion of ATP to cAMP and Pyrophosphate. In From: The Senses: A Comprehensive Reference; Academic Press: Boston, MA, USA, 2008; Available online: https://www.sciencedirect.com/topics/agricultural-and-biological-sciences/adenylate-cyclase (accessed on 29 August 2023).
  46. Roberts, R.E. The extracellular signal-regulated kinase (ERK) pathway: A potential therapeutic target in hypertension. J. Exp. Pharmacol. 2012, 4, 77–83.
  47. Lund, A.M.; Hannibal, J. Localization of the neuropeptides pituitary adenylate cyclase-activating polypeptide, vasoactive intestinal peptide, and their receptors in the basal brain blood vessels and trigeminal ganglion of the mouse CNS; an immunohistochemical study. Front. Neuroanat. 2022, 16, 991403.
  48. Ivic, I.; Balasko, M.; Fulop, B.D.; Hashimoto, H.; Toth, G.; Tamas, A.; Juhasz, T.; Koller, A.; Reglodi, D.; Solymár, M. VPAC1 receptors play a dominant role in PACAP-induced vasorelaxation in female mice. PLoS ONE 2019, 14, e0211433.
  49. VIP and PACAP Receptors—IUPHAR/BPS Guide to PHARMACOLOGY. Available online: https://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=67 (accessed on 29 August 2023).
  50. Datki, Z.; Sinka, R. Translational biomedicine-oriented exploratory research on bioactive rotifer-specific biopolymers. Adv. Clin. Exp. Med. 2022, 31, 931–935.
  51. Palotai, M.; Telegdy, G.; Tanaka, M.; Bagosi, Z.; Jászberényi, M. Neuropeptide AF induces anxiety-like and antidepressant-like behavior in mice. Behav. Brain Res. 2014, 274, 264–269.
  52. Lieb, A.; Thaler, G.; Fogli, B.; Trovato, O.; Posch, M.A.; Kaserer, T.; Zangrandi, L. Functional Characterization of Spinocerebellar Ataxia Associated Dynorphin A Mutant Peptides. Biomedicines 2021, 9, 1882.
  53. Skobeleva, K.; Shalygin, A.; Mikhaylova, E.; Guzhova, I.; Ryazantseva, M.; Kaznacheyeva, E. The STIM1/2-Regulated Calcium Homeostasis Is Impaired in Hippocampal Neurons of the 5xFAD Mouse Model of Alzheimer’s Disease. Int. J. Mol. Sci. 2022, 23, 14810.
  54. Martos, D.; Tuka, B.; Tanaka, M.; Vécsei, L.; Telegdy, G. Memory Enhancement with Kynurenic Acid and Its Mechanisms in Neurotransmission. Biomedicines 2022, 10, 849.
  55. Tanaka, M.; Szabó, Á.; Spekker, E.; Polyák, H.; Tóth, F.; Vécsei, L. Mitochondrial Impairment: A Common Motif in Neuropsychiatric Presentation? The Link to the Tryptophan–Kynurenine Metabolic System. Cells 2022, 11, 2607.
  56. Tanaka, M.; Bohár, Z.; Martos, D.; Telegdy, G.; Vécsei, L. Antidepressant-like effects of kynurenic acid in a modified forced swim test. Pharmacol. Rep. 2020, 72, 449–455.
  57. Tanaka, M.; Telegdy, G. Involvement of adrenergic and serotonergic receptors in antidepressant-like effect of urocortin 3 in a modified forced swimming test in mice. Brain Res. Bull. 2008, 77, 301–305.
  58. Tanaka, M.; Spekker, E.; Szabó, Á.; Polyák, H.; Vécsei, L. Modelling the neurodevelopmental pathogenesis in neuropsychiatric disorders. Bioactive kynurenines and their analogues as neuroprotective agents-in celebration of 80th birthday of Professor Peter Riederer. J. Neural. Transm. 2022, 129, 627–642.
  59. Reducha, P.V.; Edvinsson, L.; Haanes, K.A. Could Experimental Inflammation Provide Better Understanding of Migraines? Cells 2022, 11, 2444.
  60. Ojala, J.; Tooke, K.; Hsiang, H.; Girard, B.M.; May, V.; Vizzard, M.A. PACAP/PAC1 Expression and Function in Micturition Pathways. J. Mol. Neurosci. 2019, 68, 357–367.
  61. Tamas, A.; Reglodi, D.; Farkas, O.; Kovesdi, E.; Pal, J.; Povlishock, J.T.; Schwarcz, A.; Czeiter, E.; Szanto, Z.; Doczi, T.; et al. Effect of PACAP in central and peripheral nerve injuries. Int. J. Mol. Sci. 2012, 13, 8430–8448.
  62. Zhang, L.; Zhou, Y.; Yang, L.; Wang, Y.; Xiao, Z. PACAP6-38 improves nitroglycerin-induced central sensitization by modulating synaptic plasticity at the trigeminal nucleus caudalis in a male rat model of chronic migraine. J. Headache Pain 2023, 24, 66.
  63. Takács-Lovász, K.; Kun, J.; Aczél, T.; Urbán, P.; Gyenesei, A.; Bölcskei, K.; Szőke, É.; Helyes, Z. PACAP-38 Induces Transcriptomic Changes in Rat Trigeminal Ganglion Cells Related to Neuroinflammation and Altered Mitochondrial Function Presumably via PAC1/VPAC2 Receptor-Independent Mechanism. Int. J. Mol. Sci. 2022, 23, 2120.
  64. Frederiksen, S.D.; Haanes, K.A.; Warfvinge, K.; Edvinsson, L. Perivascular neurotransmitters: Regulation of cerebral blood flow and role in primary headaches. J. Cereb. Blood Flow Metab. 2019, 39, 610–632.
  65. Edvinsson, L.; Tajti, J.; Szalárdy, L.; Vécsei, L. PACAP and its role in primary headaches. J. Headache Pain 2018, 19, 21.
  66. Markovics, A.; Kormos, V.; Gaszner, B.; Lashgarara, A.; Szoke, E.; Sandor, K.; Szabadfi, K.; Tuka, B.; Tajti, J.; Szolcsanyi, J.; et al. Pituitary adenylate cyclase-activating polypeptide plays a key role in nitroglycerol-induced trigeminovascular activation in mice. Neurobiol. Dis. 2012, 45, 633–644.
  67. Edvinsson, L. PACAP and its receptors in migraine pathophysiology: Commentary on Walker et al. Br. J. Pharmacol. 171: 1521–1533. Br. J. Pharmacol. 2015, 172, 4782–4784.
  68. Saposnik, G.; Montalban, X.; Selchen, D.; Terzaghi, M.A.; Bakdache, F.; Montoya, A.; Fruns, M.; Caceres, F.; Oh, J. Therapeutic Inertia in Multiple Sclerosis Care: A Study of Canadian Neurologists. Front. Neurol. 2018, 9, 781.
  69. Harding, S.D.; Armstrong, J.F.; Faccenda, E.; Southan, C.; Alexander, S.P.H.; Davenport, A.P.; Pawson, A.J.; Spedding, M.; Davies, J.A.; NC-IUPHAR. The IUPHAR/BPS guide to PHARMACOLOGY in 2022: Curating pharmacology for COVID-19, malaria and antibacterials. Nucl. Acids Res. 2022, 50, D1282–D1294.
  70. Guo, S.; Jansen-Olesen, I.; Olesen, J.; Christensen, S.L. Role of PACAP in migraine: An alternative to CGRP? Neurobiol. Dis. 2023, 176, 105946.
  71. Granoth, R.; Fridkin, M.; Gozes, I. VIP and the potent analog, stearyl-Nle(17)-VIP, induce proliferation of keratinocytes. FEBS Lett. 2000, 475, 78–83.
  72. Gourlet, P.; De Neef, P.; Cnudde, J.; Waelbroeck, M.; Robberecht, P. In vitro properties of a high affinity selective antagonist of the VIP1 receptor. Peptide 1997, 18, 1555–1560.
  73. Beebe, X.; Darczak, D.; Davis-Taber, R.A.; Uchic, M.E.; Scott, V.E.; Jarvis, M.F.; Stewart, A.O. Discovery and SAR of hydrazide antagonists of the pituitary adenylate cyclase-activating polypeptide (PACAP) receptor type 1 (PAC1-R). Bioorg. Med. Chem. Lett. 2008, 18, 2162–2166.
  74. Laburthe, M.; Couvineau, A.; Tan, V. Class II G protein-coupled receptors for VIP and PACAP: Structure, models of activation and pharmacology. Peptides 2007, 28, 1631–1639.
  75. Tasma, Z.; Siow, A.; Harris, P.W.R.; Brimble, M.A.; Hay, D.L.; Walker, C.S. Characterisation of agonist signalling profiles and agonist-dependent antagonism at PACAP-responsive receptors: Implications for drug discovery. Br. J. Pharmacol. 2022, 179, 435–453.
  76. Spekker, E.; Tanaka, M.; Szabó, Á.; Vécsei, L. Neurogenic Inflammation: The Participant in Migraine and Recent Advancements in Translational Research. Biomedicines 2022, 10, 76.
  77. Pinho-Ribeiro, F.A.; Verri, W.A., Jr.; Chiu, I.M. Nociceptor Sensory Neuron-Immune Interactions in Pain and Inflammation. Trends Immunol. 2017, 38, 5–19.
  78. Guo, S.; Vollesen, A.L.; Hansen, R.D.; Esserlind, A.L.; Amin, F.M.; Christensen, A.F.; Olesen, J.; Ashina, M. Part I: Pituitary adenylate cyclase-activating polypeptide-38 induced migraine-like attacks in patients with and without familial aggregation of migraine. Cephalalgia 2017, 37, 125–135.
  79. ClinicalTrials.gov. PACAP Induced Migraine Attacks in Patients with High and Low Genetic Load. Available online: https://classic.clinicaltrials.gov/ct2/show/NCT02158221 (accessed on 29 August 2023).
  80. Togha, M.; Ghorbani, Z.; Ramazi, S.; Zavvari, F.; Karimzadeh, F. Evaluation of Serum Levels of Transient Receptor Potential Cation Channel Subfamily V Member 1, Vasoactive Intestinal Polypeptide, and Pituitary Adenylate Cyclase-Activating Polypeptide in Chronic and Episodic Migraine: The Possible Role in Migraine Transformation. Front. Neurol. 2021, 12, 770980.
  81. Körtési, T.; Tuka, B.; Tajti, J.; Bagoly, T.; Fülöp, F.; Helyes, Z.; Vécsei, L. Kynurenic Acid Inhibits the Electrical Stimulation Induced Elevated Pituitary Adenylate Cyclase-Activating Polypeptide Expression in the TNC. Front. Neurol. 2018, 8, 745.
  82. Guo, S.; Vollesen, A.L.; Hansen, Y.B.; Frandsen, E.; Andersen, M.R.; Amin, F.M.; Fahrenkrug, J.; Olesen, J.; Ashina, M. Part II: Biochemical changes after pituitary adenylate cyclase-activating polypeptide-38 infusion in migraine patients. Cephalalgia 2017, 37, 136–147.
  83. Amin, F.M.; Asghar, M.S.; Guo, S.; Hougaard, A.; Hansen, A.E.; Schytz, H.W.; van der Geest, R.J.; de Koning, P.J.; Larsson, H.B.; Olesen, J.; et al. Headache and prolonged dilatation of the middle meningeal artery by PACAP38 in healthy volunteers. Cephalalgia 2012, 32, 140–149.
  84. Maasz, G.; Zrinyi, Z.; Reglodi, D.; Petrovics, D.; Rivnyak, A.; Kiss, T.; Jungling, A.; Tamas, A.; Pirger, Z. Pituitary adenylate cyclase-activating polypeptide (PACAP) has a neuroprotective function in dopamine-based neurodegeneration in rat and snail parkinsonian models. Dis. Model Mech. 2017, 10, 127–139.
  85. Rubio-Beltrán, E.; Correnti, E.; Deen, M.; Kamm, K.; Kelderman, T.; Papetti, L.; Vigneri, S.; MaassenVanDenBrink, A.; Edvinsson, L.; European Headache Federation School of Advanced Studies (EHF-SAS). PACAP38 and PAC1 receptor blockade: A new target for headache? J. Headache Pain 2018, 19, 64.
  86. Ashina, M.; Doležil, D.; Bonner, J.H.; Zhou, L.; Klatt, J.; Picard, H.; Mikol, D.D. A phase 2, randomized, double-blind, placebo-controlled trial of AMG 301, a pituitary adenylate cyclase-activating polypeptide PAC1 receptor monoclonal antibody for migraine prevention. Cephalalgia 2021, 41, 33–44.
  87. Study to Evaluate the Efficacy and Safety of AMG 301 in Migraine Prevention 2020. Available online: https://ClinicalTrials.gov/show/NCT03238781 (accessed on 4 September 2023).
  88. Lundbeck News Room: Lundbeck Announced the Start of a Phase II Clinical Study to Assess Lu AG09222 for Migraine Prevention. Available online: https://newsroom.lundbeckus.com/news-release/2021/lundbeck-announced-start-of-phase-ii-clinical-study-for-migraine-prevention (accessed on 29 August 2023).
  89. A Study With Lu AG09222 in Adults With Migraine Who Have Not Been Helped by Prior Preventive Treatments 2023. Available online: https://classic.clinicaltrials.gov/ct2/show/NCT05133323 (accessed on 4 September 2023).
  90. A Study of LY3451838 in Participants with Migraine 2023. Available online: https://ClinicalTrials.gov/show/NCT04498910 (accessed on 4 September 2023).
  91. ClinicalTrials.gov. The Effects of a Long-Lasting Infusion of Vasoactive Intestinal Peptide (VIP) in Episodic Migraine Patients. Available online: https://classic.clinicaltrials.gov/ct2/show/NCT04260035 (accessed on 29 August 2023).
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
Upload a video for this entry
Information
Subjects: Clinical Neurology
Contributors MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register :
Masaru Tanaka
,
Ágnes Szabó
,
Tamás Körtési
,
Délia Szok
,
János Tajti
,
László Vécsei
View Times: 271
Revisions: 2 times (View History)
Update Date: 21 Nov 2023
Table of Contents
    1000/1000
    Hot Most Recent
    Feedback